Conservative and newer drug treatment for degenerative cervical myelopathy

Q2 Medicine
Osita Ede , Jason Pui Yin Cheung
{"title":"Conservative and newer drug treatment for degenerative cervical myelopathy","authors":"Osita Ede ,&nbsp;Jason Pui Yin Cheung","doi":"10.1016/j.jcot.2025.102972","DOIUrl":null,"url":null,"abstract":"<div><div>Degenerative cervical myelopathy (DCM) is the most common cause of non-traumatic spinal cord dysfunction in adults worldwide. Conservative treatments, such as physical therapy, activity modification, cervical traction, and the use of cervical collars, have been employed primarily for symptomatic relief in mild cases or for patients deemed unfit for surgery. Advances in our understanding of the molecular pathways involved in neuroinflammation and neuronal injury in DCM have spurred the development of newer pharmacological treatments aimed at neuroprotection and inflammation control. We found limited evidence that conservative treatment enhances functional recovery in patients with DCM. Patients with mild DCM who opt for conservative therapy should be aware of likely neurological deterioration and higher spinal cord injury risk following neck trauma. Nonoperative management could benefit patients with mild DCM who presented early (at least less than a year), have soft disc herniation as the cause of the myelopathy, have one level of myelopathic compression, and whose MRI does not show circumferential compression of the spinal cord. Riluzole did not replicate its promising animal results in human trials, using the modified Japanese Orthopaedic Association (mJOA) score as an outcome measure. Cerebrolysin is promising but needs more RCTs to define its role in the management algorithm. Limaprost Alfadex provided inconclusive evidence, however, is in an ongoing phase III trial. Erythropoietin showed benefit in animal and human trials but concerns over side effects may limit use. G-CSF demonstrated evidence of preserved neurological function in mice but needs human studies. Steroids did not show benefit and are likely deleterious to tissue healing and can increase infection risk. Anti-Fas ligand antibody has not been studied in humans but demonstrated benefit in animal models. Research should focus on large-scale RCTs for these drugs with careful attention to long-term effects, side effects, and finding the most effective doses.</div></div>","PeriodicalId":53594,"journal":{"name":"Journal of Clinical Orthopaedics and Trauma","volume":"64 ","pages":"Article 102972"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Orthopaedics and Trauma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0976566225000682","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Degenerative cervical myelopathy (DCM) is the most common cause of non-traumatic spinal cord dysfunction in adults worldwide. Conservative treatments, such as physical therapy, activity modification, cervical traction, and the use of cervical collars, have been employed primarily for symptomatic relief in mild cases or for patients deemed unfit for surgery. Advances in our understanding of the molecular pathways involved in neuroinflammation and neuronal injury in DCM have spurred the development of newer pharmacological treatments aimed at neuroprotection and inflammation control. We found limited evidence that conservative treatment enhances functional recovery in patients with DCM. Patients with mild DCM who opt for conservative therapy should be aware of likely neurological deterioration and higher spinal cord injury risk following neck trauma. Nonoperative management could benefit patients with mild DCM who presented early (at least less than a year), have soft disc herniation as the cause of the myelopathy, have one level of myelopathic compression, and whose MRI does not show circumferential compression of the spinal cord. Riluzole did not replicate its promising animal results in human trials, using the modified Japanese Orthopaedic Association (mJOA) score as an outcome measure. Cerebrolysin is promising but needs more RCTs to define its role in the management algorithm. Limaprost Alfadex provided inconclusive evidence, however, is in an ongoing phase III trial. Erythropoietin showed benefit in animal and human trials but concerns over side effects may limit use. G-CSF demonstrated evidence of preserved neurological function in mice but needs human studies. Steroids did not show benefit and are likely deleterious to tissue healing and can increase infection risk. Anti-Fas ligand antibody has not been studied in humans but demonstrated benefit in animal models. Research should focus on large-scale RCTs for these drugs with careful attention to long-term effects, side effects, and finding the most effective doses.
退行性颈椎病的保守和新药物治疗
退行性脊髓型颈椎病(DCM)是世界范围内成人非创伤性脊髓功能障碍的最常见原因。保守治疗,如物理治疗、活动调节、颈椎牵引和颈圈的使用,主要用于轻度病例或被认为不适合手术的患者的症状缓解。我们对DCM中涉及神经炎症和神经元损伤的分子通路的理解的进步刺激了旨在神经保护和炎症控制的新药物治疗的发展。我们发现有限的证据表明保守治疗可以促进DCM患者的功能恢复。选择保守治疗的轻度DCM患者应注意颈部外伤后可能出现的神经功能恶化和更高的脊髓损伤风险。非手术治疗对早期(至少少于一年)轻度DCM患者有利,这些患者的病因为脊髓病的椎间盘突出,有一定程度的脊髓压迫,MRI未显示脊髓周向压迫。利鲁唑没有在人体试验中复制其有希望的动物结果,使用改良的日本骨科协会(mJOA)评分作为结果衡量标准。脑溶血素很有前景,但需要更多的随机对照试验来确定其在管理算法中的作用。然而,limapprost Alfadex提供了不确定的证据,该药物正在进行III期试验。促红细胞生成素在动物和人体试验中显示出益处,但对副作用的担忧可能会限制使用。G-CSF在小鼠中显示了保留神经功能的证据,但需要在人体中进行研究。类固醇没有显示出益处,而且可能对组织愈合有害,并可能增加感染风险。抗fas配体抗体尚未在人体中进行研究,但在动物模型中显示出益处。研究应该集中在这些药物的大规模随机对照试验上,仔细关注长期效应、副作用,并找到最有效的剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Orthopaedics and Trauma
Journal of Clinical Orthopaedics and Trauma Medicine-Orthopedics and Sports Medicine
CiteScore
4.30
自引率
0.00%
发文量
181
审稿时长
92 days
期刊介绍: Journal of Clinical Orthopaedics and Trauma (JCOT) aims to provide its readers with the latest clinical and basic research, and informed opinions that shape today''s orthopedic practice, thereby providing an opportunity to practice evidence-based medicine. With contributions from leading clinicians and researchers around the world, we aim to be the premier journal providing an international perspective advancing knowledge of the musculoskeletal system. JCOT publishes content of value to both general orthopedic practitioners and specialists on all aspects of musculoskeletal research, diagnoses, and treatment. We accept following types of articles: • Original articles focusing on current clinical issues. • Review articles with learning value for professionals as well as students. • Research articles providing the latest in basic biological or engineering research on musculoskeletal diseases. • Regular columns by experts discussing issues affecting the field of orthopedics. • "Symposia" devoted to a single topic offering the general reader an overview of a field, but providing the specialist current in-depth information. • Video of any orthopedic surgery which is innovative and adds to present concepts. • Articles emphasizing or demonstrating a new clinical sign in the art of patient examination is also considered for publication. Contributions from anywhere in the world are welcome and considered on their merits.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信